Lev Demidov

Research interests

Publications

• Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2304753

• Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

  Journal of Clinical Oncology · 2022 · 10.1200/jco.22.00343

• Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(22)00687-8

• 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

  Clinical Cancer Research · 2021 · 10.1158/1078-0432.ccr-21-0809

• Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2103485

• Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

  Nature Medicine · 2021 · 10.1038/s41591-021-01510-7

• Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.12.004

• Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

  European Journal of Cancer · 2020 · 10.1016/j.ejca.2019.10.033

• Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)30934-x

• Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2019.07.010

• Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30274-8

• Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2018.12.015

• MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30254-7

• Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2018.36.15_suppl.108

• Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30180-8

• Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

  ESMO Open · 2016 · 10.1136/esmoopen-2016-000068

• Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30122-x

• Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1408868

• An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2013.31.15_suppl.9013

• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  Zurich Open Repository and Archive (University of Zurich) · 2012 · 10.5167/uzh-63198

• Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1203421

• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)60868-x

Current projects

No projects listed.